MedTrace Logo

WIRE - Novel Treatments in Renal Cell Cancer

NCT03741426 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-06-07

No results posted yet for this study

Summary

Evaluation of proof of mechanism with relation to ktrans and/or CD8 count when 3 different IMPs are given as monotherapy or as combination therapy. These would be administered in the "window of opportunity", prior to nephrectomy in surgically resectable renal cell cancer

Conditions

  • Renal Cell Cancer

Interventions

DRUG

Olaparib

Olaparib 300mg twice daily, oral medication administered for at least 2 weeks and up until the morning of nephrectomy. Arms 2, 3 and 5

DRUG

Cediranib

Cediranib 20mg once daily, oral medication administered for at least 2 weeks until 36 hours prior to nephrectomy. Arms 1 and 3

DRUG

Durvalumab

Durvalumab 1500mg intravenous infusion administered once, no greater than 4 weeks prior to nephrectomy

Sponsors & Collaborators

Principal Investigators

  • Grant D Stewart · Cambridge University Hospitals NHS Foundation Trust & University of Cambridge

  • Brent O'Carrigan · Cambridge University Hospitals NHS Foundation Trust & University of Cambridge

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-27
Primary Completion
2025-11-30
Completion
2025-11-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03741426 on ClinicalTrials.gov